CN102160861A - Infusion medicament analgesic patch - Google Patents
Infusion medicament analgesic patch Download PDFInfo
- Publication number
- CN102160861A CN102160861A CN2010101127340A CN201010112734A CN102160861A CN 102160861 A CN102160861 A CN 102160861A CN 2010101127340 A CN2010101127340 A CN 2010101127340A CN 201010112734 A CN201010112734 A CN 201010112734A CN 102160861 A CN102160861 A CN 102160861A
- Authority
- CN
- China
- Prior art keywords
- pain relieving
- solution
- absorption pad
- lidocaine hydrochloride
- mass percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to an external medicament, in particular to an infusion medicament analgesic patch which is used for relieving pain in the process of intravenous infusion. The patch comprises a polyurethane transparent film and an absorbent pad fixed on the polyurethane transparent film, wherein the analgesic liquid medicine soaked in the absorbent pad is formed by mixing a nitroglycerin solution the mass percent concentration of which is 2-3% and a lidocaine hydrochloride solution the mass percent concentration of which is 0.5-1.5%, and the volume ratio of the nitroglycerin solution to the lidocaine hydrochloride solution is (2.5-3.5):1. When a patient is treated by intravenous infusion of medicaments such as potassium chloride and the like, the analgesic patch can effectively relieve the pain caused by infusion of the medicaments and has higher safety in clinical application.
Description
Technical field
The present invention relates to a kind of medicine for external use, particularly when venous transfusion, be used for the pain relieving of analgesic flow of infusate and paste.
Background technology
The venous transfusion kalium replenishment is widely used in clinical vein transfusion, fasting patient particularly, and every day, vein replenished a certain amount of potassium, was the clinical Therapeutic Method that must adopt.But the medicine such as potassium chloride is bigger to the zest of local skin, tissue, and can cause phlebitis, and pain is obvious.Because potassium ion is to cause the pain factor, after in the potassium chloride input body, except that the physical stimulation of self, still can cause neurotransmitter such as adrenal gland in the body, the rising in various degree of materials such as 5-hydroxy tryptamine, bring out nociceptive reflex, and neural many companion's row of reaction pain degree are in the venous access of kalium replenishment, its epidermis that mainly is positioned at the vein superficial surface that distributes is subcutaneous, and near health tip top layer, sensorineural bundle district ratio is big more, and pain sensitivity is high more, and the pain that causes is strong further, and pain can be gone with the transfusion companion, cause the persistent pain of patient, fear, so there is quite a few patient to bear pain that can't stand transfusion, this not only brings great misery to patient, but also cause medicine not import according to quantity on time, incur loss through delay patient's the state of an illness.
Summary of the invention
The purpose of this invention is to provide a kind of flow of infusate pain relieving and paste, when patient is carried out the venous transfusion of medicine such as potassium chloride, can effectively alleviate in the infusion process because the drug induced pain of failing.
Flow of infusate pain relieving of the present invention is pasted, comprise polyurethane hyaline membrane and absorption pad fixed thereon, be soaked with the pain relieving medicinal liquid in the absorption pad, described pain relieving medicinal liquid is that 2～3% nitroglycerin solution and mass percent concentration are that 0.5～1.5% lidocaine hydrochloride solution mixes by mass percent concentration, and the volume ratio of nitroglycerin solution and lidocaine hydrochloride solution is 1.5～2.5: 1.
In every cubic centimetre absorption pad, be soaked with the described pain relieving medicinal liquid of 1～2ml.
During use, be after treating that the venous patient vein puncture is finished, wrapping film pasted in this pain relieving open, the absorption pad that pain relieving is pasted is applied to the puncture vessel proximal part, apart from point of puncture 2～3cm place, raised transfusion part 20～30 degree about 2 minutes, treat after the venous patient transfusion finishes the pain relieving subsides to be thrown off.
Lidocaine hydrochloride is a kind of traditional local anesthetic, can be water-soluble, can especially have certain penetration power through skin and mucosa absorption to skin, mucosa.Nitroglycerin is a kind of smooth muscle relaxant, has the effect that blood vessel dilating increases regional blood flow, also has the good transdermal absorbability.Nitroglycerin generates NO in the vascular endothelial cell in vivo, makes GTP be converted into cGTP, and activator protein enzyme G closes calcium channel, potassium channels opening, thus make the vascular smooth muscle diastole.And the accumulation infiltration capacity and the time of penetration of lidocaine hydrochloride, nitroglycerin are good linear relationship, and the transdermal penetration process does not have time lag, in 0～40min scope with the first-rate release.Wherein the skin unit area of lidocaine hydrochloride 2min is accumulated infiltration capacity (μ g/m
2) can reach 2.35, rapid-action; The transdermal penetration test of lidocaine hydrochloride and nitroglycerin does not all have time lag (Tlag＜0), sees through with zero level speed in 0～40min scope.
Flow of infusate pain relieving of the present invention is pasted through routine clinical practice surplus 150, can effectively alleviate the pain of vein kalium replenishment, and the one or many medication react intact skin nonirritant, and skin is not had sensitization, so in clinical use higher safety is arranged; Through accelerated test, long term test, the character of solution is still stable, and pH value does not have remarkable fluctuation,, the changes of contents of Main Ingredients and Appearance all in limits, good stability.
The specific embodiment
Embodiment one:
This flow of infusate pain relieving is pasted and is comprised that the one side that polyurethane hyaline membrane and absorption pad fixed thereon, polyurethane hyaline membrane are fixed with absorption pad has the inferior quick glue of low sensitization.Absorption pad is made by medical absorption sponge, be soaked with the pain relieving medicinal liquid in the absorption pad, the pain relieving medicinal liquid is that 2% nitroglycerin solution and mass percent concentration are that 1.5% lidocaine hydrochloride solution mixes by mass percent concentration, and the volume ratio of nitroglycerin solution and lidocaine hydrochloride solution is 1.5: 1, is soaked with this pain relieving medicinal liquid of 1ml in every cubic centimetre the absorption pad.
Embodiment two:
This flow of infusate pain relieving is pasted and is comprised that the one side that polyurethane hyaline membrane and absorption pad fixed thereon, polyurethane hyaline membrane are fixed with absorption pad has the inferior quick glue of low sensitization.Absorption pad is made by medical absorption sponge, be soaked with the pain relieving medicinal liquid in the absorption pad, the pain relieving medicinal liquid is that 3% nitroglycerin solution and mass percent concentration are that 0.5% lidocaine hydrochloride solution mixes by mass percent concentration, and the volume ratio of nitroglycerin solution and lidocaine hydrochloride solution is 2.5: 1, is soaked with this pain relieving medicinal liquid of 2ml in every cubic centimetre the absorption pad.
Embodiment three:
This flow of infusate pain relieving is pasted and is comprised that the one side that polyurethane hyaline membrane and absorption pad fixed thereon, polyurethane hyaline membrane are fixed with absorption pad has the inferior quick glue of low sensitization.Absorption pad is made by medical absorption sponge, be soaked with the pain relieving medicinal liquid in the absorption pad, the pain relieving medicinal liquid is that 2.5% nitroglycerin solution and mass percent concentration are that 1% lidocaine hydrochloride solution mixes by mass percent concentration, and the volume ratio of nitroglycerin solution and lidocaine hydrochloride solution is 2: 1, is soaked with this pain relieving medicinal liquid of 1.5ml in every cubic centimetre the absorption pad.
Claims (2)
1. a flow of infusate pain relieving is pasted, comprise polyurethane hyaline membrane and absorption pad fixed thereon, be soaked with the pain relieving medicinal liquid in the absorption pad, it is characterized in that: described pain relieving medicinal liquid is that 2～3% nitroglycerin solution and mass percent concentration are that 0.5～1.5% lidocaine hydrochloride solution mixes by mass percent concentration, and the volume ratio of nitroglycerin solution and lidocaine hydrochloride solution is 1.5～2.5: 1.
2. described flow of infusate pain relieving is pasted according to claim 1, it is characterized in that: the described pain relieving medicinal liquid that is soaked with 1～2ml in every cubic centimetre the absorption pad.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101127340A CN102160861A (en) | 2010-02-23 | 2010-02-23 | Infusion medicament analgesic patch |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101127340A CN102160861A (en) | 2010-02-23 | 2010-02-23 | Infusion medicament analgesic patch |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102160861A true CN102160861A (en) | 2011-08-24 |
Family
ID=44462487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101127340A Pending CN102160861A (en) | 2010-02-23 | 2010-02-23 | Infusion medicament analgesic patch |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102160861A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104367416A (en) * | 2014-11-07 | 2015-02-25 | 薛景 | Fast pain relieving method for children blood vessel puncture and pain relieving paste |
| CN107648530A (en) * | 2017-11-02 | 2018-02-02 | 青海喜玛拉雅药业有限公司 | Pain relieving plaster |
-
2010
- 2010-02-23 CN CN2010101127340A patent/CN102160861A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104367416A (en) * | 2014-11-07 | 2015-02-25 | 薛景 | Fast pain relieving method for children blood vessel puncture and pain relieving paste |
| CN107648530A (en) * | 2017-11-02 | 2018-02-02 | 青海喜玛拉雅药业有限公司 | Pain relieving plaster |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7440798B2 (en) | Substance delivery system | |
| CN107007927A (en) | A kind of microneedle array drug paste and preparation method being administered based on electric field driven | |
| WO2009105564A2 (en) | Acupuncture and acupressure therapies | |
| WO2009043031A3 (en) | Microbubbles and methods for oxygen delivery | |
| CN110381930A (en) | The percutaneous and transdermal administration of treprostinil and its salt | |
| WO2017079764A1 (en) | Method for the attenuation enhancement of absorbent materials used in both passive and active transdermal drug delivery systems | |
| EP2908873A1 (en) | Transdermal delivery system | |
| CN105579074A (en) | Dressing system | |
| CN201320240Y (en) | External constant-temperature traditional Chinese percutaneous medicine plaster | |
| EP1471838A2 (en) | Substance delivery device | |
| CN102160861A (en) | Infusion medicament analgesic patch | |
| CN100540067C (en) | Sterilized magnesium sulfate dressing preparation | |
| CN104706777A (en) | Traditional Chinese medicine narcotic analgesic for treating hip replacement postoperation pain | |
| CN107019843A (en) | negative pressure transdermal delivery device | |
| AR053799A1 (en) | COMPOSITIONS CONTAINING POLYCONASOL AND TEAFLAVINE AND ITS PHARMACEUTICAL USES | |
| CN208641524U (en) | A kind of Adlerika soak packet | |
| CN100500139C (en) | External use medicine for treating rheumatic arthritis, and its preparation method | |
| KR102178353B1 (en) | patch composition for diabetes mellitus and patch manufacturing method using the same | |
| CN113521290B (en) | Pharmaceutical composition, medicinal patch, and preparation method and application thereof | |
| Chavan et al. | A Simple Glance At The Transdermal Drug Delivery System | |
| Lee et al. | Nonemergency use of slow infusions of diazoxide | |
| CN201612748U (en) | Biological pasted hot compress bag for dissolving stasis | |
| Boudjenah | Advocacy for Carbomedtherapy (Carbon Dioxide Therapy) in the Treatment of Diabetic Neuropathy | |
| Deulkar et al. | A review on transdermal drug delivery system | |
| CN210170668U (en) | Micro-needle point medicine patch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110824 |